## **Resource Summary Report**

Generated by ASWG on May 1, 2025

# University of Pennsylvania Perelman School of Medicine Ovarian Cancer Research Center Tumor BioTrust Collection Core Facility

RRID:SCR\_022387

Type: Tool

## **Proper Citation**

University of Pennsylvania Perelman School of Medicine Ovarian Cancer Research Center Tumor BioTrust Collection Core Facility (RRID:SCR\_022387)

#### Resource Information

URL: https://www.med.upenn.edu/OCRCBioTrust/

**Proper Citation:** University of Pennsylvania Perelman School of Medicine Ovarian Cancer Research Center Tumor BioTrust Collection Core Facility (RRID:SCR 022387)

**Description:** Provides specimens including gynecologic cancer specimens such as fresh and frozen tissues, plasma, serum, peripheral blood mononuclear cells, blood, formalin fixed paraffin embedded (FFPE) samples, and Tissue Microarrays (TMAs). All samples collected have clinical annotation including demographic patient profiles, pathological and clinical notations, treatment history, and detail disease information, etc. We are building and maintaining centralized research database according to HIPPA specifications and Penn IRB standards.

Abbreviations: OCRC TBC

**Synonyms:** University of Pennsylvania Perelman School of Medicine OCRC Tumor BioTrust Collection, OCRC Tumor BioTrust Collection

Resource Type: service resource, core facility, access service resource

Keywords: USEDit, ABRF

**Funding:** 

Availability: open

Resource Name: University of Pennsylvania Perelman School of Medicine Ovarian Cancer

Research Center Tumor BioTrust Collection Core Facility

Resource ID: SCR\_022387

Alternate IDs: ARBF\_1379

Alternate URLs: https://coremarketplace.org?citation=1&FacilityID=1379

**Record Creation Time:** 20220602T050140+0000

Record Last Update: 20250501T081621+0000

## Ratings and Alerts

No rating or validation information has been found for University of Pennsylvania Perelman School of Medicine Ovarian Cancer Research Center Tumor BioTrust Collection Core Facility.

No alerts have been found for University of Pennsylvania Perelman School of Medicine Ovarian Cancer Research Center Tumor BioTrust Collection Core Facility.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at <u>ASWG</u>.

Medina JE, et al. (2025) Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers. Cancer discovery, 15(1), 105.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978.

Tubridy EA, et al. (2024) CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival. Gynecologic oncology, 184, 74.

Hippen AA, et al. (2023) Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors. Genome biology, 24(1), 239.

Restaino AC, et al. (2023) Functional neuronal circuits promote disease progression in cancer. Science advances, 9(19), eade4443.

Taylor MS, et al. (2023) Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer discovery, 13(12), 2532.

Taylor MS, et al. (2023) Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. bioRxiv: the preprint server for biology.

Bustos MA, et al. (2023) MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell & bioscience, 13(1), 200.